摘要
随着免疫检查点抑制剂(ICI)在肿瘤患者中的广泛应用,免疫相关不良事件愈发受到关注。程序性细胞死亡蛋白-1(PD-1)和程序性细胞死亡配体-1(PD-L1)在人心肌细胞中表达,因此应用PD-1/PDL-1抑制剂的同时,可能会对心血管系统造成诸多不良反应。本文综述了PD-1/PD-L1抑制剂心血管毒性的最新流行病学证据、临床表现以及潜在的病理机制及目前的诊疗方法,以期为ICI毒性监测和制定治疗策略提供新的视角。
With the wide application of immune checkpoint inhibitors(ICIs) in tumor patients, immune related adverse events have attracted more attention. PD-1 and PD-L1 are expressed in human cardiomyocytes, so the application of PD-1/PDL-1 inhibitors can cause many adverse reactions to the cardiovascular system. This review summarizes the latest epidemiological evidence on the cardiovascular toxicity of programmed cell death protein-1(PD-1)/programmed cell death ligand-1(PD-L1) inhibitors and the clinical manifestations, as well as the potential pathological mechanisms and current diagnosis and treatment strategies. These updates may provide a novel perspective for monitoring early toxicity and establishing appropriate treatment for patients with ICI-related cardiotoxicity.
作者
刘德敏
路旭阳
谷国强
LIU Demin;LU Xuyang;GU Guoqiang(Department of Cardiology,The Second Hospital of Hebei Medical University,Shijiazhuang,050000,China)
出处
《临床心血管病杂志》
CAS
北大核心
2023年第6期481-486,共6页
Journal of Clinical Cardiology
基金
国家自然科学基金(No:82100301)
河北省自然科学基金精准医学联合重点项目(No:H2020206409)。
